Search research articles
Contact Us
Filters
Showing results (31-40 of 61) with videos related to
Page
of 7
Sort By:
The Lancet. Haematology
|
March 29, 2023
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study
Guillermo Garcia-Manero, Aaron D Goldberg, Eric S Winer, et al.
American Journal of Hematology
|
March 26, 2022
Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival
Talha Badar, Ehab Atallah, Rory M Shallis, et al.
Leukemia
|
February 22, 2023
Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Talha Badar, Ehab Atallah, Rory Shallis, et al.
Blood Advances
|
June 27, 2020
Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure
Brian J Ball, Christopher A Famulare, Eytan M Stein, et al.
Blood Advances
|
December 6, 2025
Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure
Kuo-Kai Chin, Brian J Ball, Yasmin Abaza, et al.
Blood Cancer Journal
|
February 20, 2024
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Talha Badar, Ahmad Nanaa, Ehab Atallah, et al.
Blood Cancer Journal
|
October 7, 2025
Outcomes of older patients with TP53-mutated myeloid neoplasms
Omer Jamy, Mobachir El Kettani, Kashish Shah, et al.
Molecular Genetics and Metabolism
|
April 15, 2017
Brain MRS glutamine as a biomarker to guide therapy of hyperammonemic coma
Anne H O'Donnell-Luria, Alexander P Lin, Sai K Merugumala, et al.
British Journal of Haematology
|
May 22, 2025
Heterogeneity in outcomes of TP53-mutated myeloproliferative neoplasms based on disease phenotype and mutational status
Talha Badar, James M Foran, Jan Philipp Bewersdorf, et al.
Leukemia & Lymphoma
|
June 10, 2024
<i>TP53</i> Y220C mutations in patients with myeloid malignancies
Georgina Gener-Ricos, Jan P Bewersdorf, Sanam Loghavi, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 61) with videos related to
Sort By:
Page
of 7
The Lancet. Haematology
|
March 29, 2023
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study
Guillermo Garcia-Manero, Aaron D Goldberg, Eric S Winer, et al.
American Journal of Hematology
|
March 26, 2022
Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival
Talha Badar, Ehab Atallah, Rory M Shallis, et al.
Leukemia
|
February 22, 2023
Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Talha Badar, Ehab Atallah, Rory Shallis, et al.
Blood Advances
|
June 27, 2020
Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure
Brian J Ball, Christopher A Famulare, Eytan M Stein, et al.
Blood Advances
|
December 6, 2025
Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure
Kuo-Kai Chin, Brian J Ball, Yasmin Abaza, et al.
Blood Cancer Journal
|
February 20, 2024
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Talha Badar, Ahmad Nanaa, Ehab Atallah, et al.
Blood Cancer Journal
|
October 7, 2025
Outcomes of older patients with TP53-mutated myeloid neoplasms
Omer Jamy, Mobachir El Kettani, Kashish Shah, et al.
Molecular Genetics and Metabolism
|
April 15, 2017
Brain MRS glutamine as a biomarker to guide therapy of hyperammonemic coma
Anne H O'Donnell-Luria, Alexander P Lin, Sai K Merugumala, et al.
British Journal of Haematology
|
May 22, 2025
Heterogeneity in outcomes of TP53-mutated myeloproliferative neoplasms based on disease phenotype and mutational status
Talha Badar, James M Foran, Jan Philipp Bewersdorf, et al.
Leukemia & Lymphoma
|
June 10, 2024
<i>TP53</i> Y220C mutations in patients with myeloid malignancies
Georgina Gener-Ricos, Jan P Bewersdorf, Sanam Loghavi, et al.
Page
of 7